PRP38 Antibody

What is the PRP38 protein and what is its cellular function?

PRP38 (Pre-mRNA Processing Factor 38) proteins are components of the spliceosome complex that play crucial roles in pre-mRNA splicing. PRPF38B is a unique component of the U4/U6.U5 tri-small nuclear ribonuclear protein (snRNP) particle and is necessary for an essential step in late spliceosome maturation . Similarly, PRPF38A is a key component of the spliceosome complex involved in ensuring the correct splicing of pre-mRNA molecules .

The spliceosome processes pre-mRNA by removing introns and joining exons, which is a critical step in gene expression. Dysfunction in this machinery has been linked to various diseases, including neurological disorders and cancer . PRP38 proteins have been identified in various organisms from yeast (Saccharomyces cerevisiae and Schizosaccharomyces pombe) to complex eukaryotes like humans, indicating their evolutionary conservation and biological importance .

What applications are PRP38 antibodies suitable for?

PRP38 antibodies are suitable for multiple experimental applications depending on the specific antibody:

When selecting the appropriate antibody for your experiment, consider the target species, application requirements, and available validation data. It's important to note that optimal dilutions may be sample-dependent, and titration in your specific testing system is recommended for optimal results .

How should PRP38 antibodies be stored and handled?

Proper storage and handling of PRP38 antibodies are crucial for maintaining their activity and specificity:

• PRPF38B antibody (23901-1-AP): Store at -20°C in PBS with 0.02% sodium azide and 50% glycerol (pH 7.3). The antibody is stable for one year after shipment when stored properly. Aliquoting is unnecessary for -20°C storage. The 20μl sizes contain 0.1% BSA .

• PRPF38A antibody (PACO05548): Store in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide .

When working with antibodies, follow these general guidelines:

• Avoid repeated freeze-thaw cycles

• Centrifuge briefly before opening the vial

• Work with antibodies on ice when possible

• Avoid contamination

• Follow manufacturer's recommendations for reconstitution if applicable

How should I validate the specificity of a PRP38 antibody for my experiments?

Validating antibody specificity is crucial for ensuring reliable experimental results. For PRP38 antibodies, consider the following validation approaches:

• Western blot analysis: Compare the observed molecular weight with the expected size. For instance, PRPF38B has a calculated molecular weight of 64 kDa but is observed at 65-70 kDa in Western blots . This slight discrepancy is normal due to post-translational modifications.

• Positive controls: Use cell lines known to express the target. For PRPF38B, HEK-293, K-562, and NIH/3T3 cells have been confirmed as positive controls .

• Cross-reactivity testing: Verify reactivity with your species of interest. PRPF38B antibody (23901-1-AP) has been tested for reactivity with human and mouse samples , while PRPF38A antibody (PACO05548) also reacts with human and mouse samples .

• Knockdown/knockout validation: If possible, use siRNA knockdown or CRISPR knockout samples as negative controls.

• Peptide competition assay: Pre-incubate the antibody with the immunogen peptide to confirm signal specificity.

Always include appropriate controls and validate the antibody in your specific experimental context before proceeding with larger studies.

What are the optimal conditions for Western blot detection of PRP38 proteins?

Achieving optimal Western blot results for PRP38 proteins requires attention to several factors:

• Sample preparation:

  • Use appropriate lysis buffers that preserve protein integrity

  • Include protease inhibitors to prevent degradation

  • Denature samples in loading buffer containing SDS and reducing agents

• Gel electrophoresis:

  • Use 10-12% SDS-PAGE gels for optimal separation

  • Load appropriate amount of protein (typically 20-40 μg of total protein)

• Transfer and blocking:

  • Use PVDF or nitrocellulose membranes

  • Block with 5% non-fat milk or BSA in TBST

• Antibody incubation:

  • For PRPF38B: Use at 1:500-1:1000 dilution

  • For PRPF38A: Use at 1:500-1:2000 dilution

  • Incubate at 4°C overnight for primary antibody

• Detection:

  • Use appropriate secondary antibody (anti-rabbit IgG for both PRPF38A and PRPF38B antibodies)

  • Optimize exposure time to avoid background while maintaining signal

• Expected results:

  • PRPF38B appears at 65-70 kDa

  • Validate results using positive control cells such as HEK-293, K-562, or NIH/3T3

Remember that sample-dependent optimization may be necessary, and following the manufacturer's protocol is recommended for initial experiments.

How can I use PRP38 antibodies to investigate spliceosome assembly in disease models?

Investigating spliceosome assembly in disease models with PRP38 antibodies requires sophisticated experimental approaches:

• Co-immunoprecipitation (Co-IP):

  • Use PRP38 antibodies to pull down associated spliceosome components

  • Analyze protein interactions by Western blot or mass spectrometry

  • Compare interaction patterns between normal and disease states

• Immunofluorescence microscopy:

  • Visualize subcellular localization of PRP38 proteins

  • Examine co-localization with other spliceosome components

  • Compare distribution patterns in normal versus diseased cells

• Chromatin immunoprecipitation (ChIP):

  • Investigate association of PRP38 with chromatin during co-transcriptional splicing

  • Analyze differences in binding patterns in disease models

• RNA immunoprecipitation (RIP):

  • Identify RNA targets bound by PRP38 during splicing

  • Compare RNA binding profiles between normal and pathological conditions

• Proximity ligation assay (PLA):

  • Detect and quantify protein-protein interactions involving PRP38 in situ

  • Evaluate how these interactions are altered in disease states

When designing such experiments, consider using PRPF38A antibody for human or mouse disease models, as dysregulation of PRPF38A has been linked to various diseases, including neurological disorders and cancer . Ensure proper optimization of antibody concentrations and experimental conditions for each application.

What are the key considerations for immunohistochemical detection of PRP38 proteins in tissue samples?

Immunohistochemical (IHC) detection of PRP38 proteins in tissue samples requires careful attention to several technical aspects:

• Tissue preparation:

  • Proper fixation is crucial (typically 10% neutral buffered formalin)

  • Consider antigen retrieval methods (heat-induced or enzymatic)

  • Use positive control tissues to validate staining

• Antibody selection and optimization:

  • PRPF38A antibody (PACO05548) is recommended for IHC at dilutions of 1:100-1:300

  • Perform antibody titration to determine optimal concentration

  • Include isotype controls to assess non-specific binding

• Detection systems:

  • Select appropriate detection system (HRP-DAB, AP-Red, fluorescence)

  • Consider signal amplification for low-abundance targets

  • Optimize incubation times and temperatures

• Image analysis and quantification:

  • Use digital pathology tools for quantitative analysis

  • Establish clear criteria for positive staining

  • Employ appropriate statistical methods for comparing samples

• Interpretation challenges:

  • PRP38 proteins primarily localize to the nucleus, specifically in splicing speckles

  • Distinguish between specific nuclear staining and background

  • Consider dual staining with other splicing factors for co-localization studies

• Troubleshooting:

  • High background: Increase blocking time or antibody dilution

  • Weak signal: Optimize antigen retrieval, decrease antibody dilution

  • Non-specific staining: Increase washing steps, use more stringent blocking

When examining tissue samples from disease models, compare expression patterns and subcellular localization between normal and pathological tissues to identify potential alterations in PRP38 distribution that may contribute to disease mechanisms.

How can I troubleshoot non-specific bands in Western blots using PRP38 antibodies?

Non-specific bands are a common challenge in Western blotting. When using PRP38 antibodies, consider these troubleshooting approaches:

• Optimize antibody dilution:

  • Start with the recommended dilution range (1:500-1:1000 for PRPF38B , 1:500-1:2000 for PRPF38A )

  • Increase dilution if non-specific bands are prominent

• Improve blocking:

  • Use 5% non-fat milk or BSA in TBST

  • Increase blocking time to 1-2 hours at room temperature

  • Consider different blocking reagents if background persists

• Enhance washing:

  • Increase number and duration of wash steps

  • Use fresh TBST for each wash

• Adjust sample preparation:

  • Include protease inhibitors to prevent degradation fragments

  • Ensure complete protein denaturation

  • Filter lysates to remove cellular debris

• Confirm target identity:

  • Remember that PRPF38B appears at 65-70 kDa, which may differ slightly from the calculated 64 kDa

  • Use positive control samples (HEK-293, K-562, NIH/3T3 cells for PRPF38B )

  • Consider peptide competition assays to confirm specificity

• Address cross-reactivity:

  • Validate antibody specificity for your species of interest

  • Consider using more specific monoclonal antibodies if available

Non-specific bands could also represent isoforms, degradation products, or post-translationally modified variants of the target protein. Careful analysis and multiple validation approaches may be needed to distinguish these possibilities.

What are the considerations for using PRP38 antibodies in multiplex immunoassays?

Multiplex immunoassays allow simultaneous detection of multiple targets, offering advantages for studying complex processes like splicing. When incorporating PRP38 antibodies in multiplex assays, consider:

• Antibody compatibility:

  • Ensure primary antibodies are from different host species to avoid cross-reactivity

  • If using multiple rabbit antibodies (like PRPF38A and PRPF38B), consider sequential staining or specialized multiplex kits

• Signal separation:

  • Use fluorophores with minimal spectral overlap

  • Plan appropriate filter sets and detection channels

  • Consider sequential acquisition for closely overlapping signals

• Validation controls:

  • Single-stain controls to establish baseline signals

  • Fluorescence-minus-one (FMO) controls to assess spillover

  • Isotype controls to evaluate non-specific binding

• Antibody panel design:

  • Include markers for subcellular compartments (e.g., nuclear markers)

  • Consider adding other spliceosome components for co-localization studies

  • Choose markers with sufficient expression level differences

• Optimization strategies:

  • Titrate each antibody individually before combining

  • Test different fixation and permeabilization protocols

  • Optimize incubation times and temperatures

• Data analysis:

  • Use appropriate software for spectral unmixing if needed

  • Employ quantitative co-localization analyses

  • Consider machine learning approaches for complex pattern recognition

When designing multiplex experiments to study spliceosome dynamics, consider combining PRPF38A or PRPF38B antibodies with antibodies against other spliceosome components to investigate protein-protein interactions and co-localization patterns under different experimental conditions.

How can PRP38 antibodies be used to study the role of splicing factors in cancer progression?

Dysregulation of splicing machinery, including PRP38 proteins, has been implicated in cancer development and progression. PRP38 antibodies can be valuable tools in cancer research:

• Expression profiling:

  • Compare PRP38 expression levels between normal and cancer tissues

  • Correlate expression with clinical parameters and patient outcomes

  • Identify potential biomarkers for cancer diagnosis or prognosis

• Alternative splicing analysis:

  • Investigate how PRP38 alterations affect splicing patterns of cancer-related genes

  • Combine immunoprecipitation with RNA-seq to identify PRP38-dependent splicing events

  • Correlate splicing changes with cancer phenotypes

• Functional studies:

  • Use PRP38 antibodies in combination with knockdown/overexpression approaches

  • Monitor changes in cell proliferation, migration, and invasion

  • Assess drug sensitivity in relation to PRP38 expression levels

• Therapy resistance mechanisms:

  • Investigate whether alterations in PRP38 contribute to treatment resistance

  • Compare PRP38 expression in sensitive versus resistant cancer cells

  • Identify targetable vulnerabilities in splicing-dysregulated cancers

• Experimental approaches:

  • Tissue microarray analysis using PRPF38A antibody at 1:100-1:300 dilutions

  • Western blot analysis of cancer cell lines using optimized antibody concentrations

  • Chromatin immunoprecipitation to identify genomic binding sites

Since dysregulation of PRPF38A has been linked to cancer , using specific antibodies to monitor its expression and interactions could provide insights into the molecular mechanisms underlying cancer progression and potential therapeutic strategies targeting splicing machinery.

What methodological approaches can be used to investigate post-translational modifications of PRP38 proteins?

Post-translational modifications (PTMs) can significantly impact PRP38 protein function, localization, and interactions. Investigating these modifications requires specialized approaches:

• PTM-specific detection methods:

  • Phospho-specific antibodies (if available)

  • Phos-tag gels for detecting phosphorylated forms

  • Ubiquitination and SUMOylation assays

• Mass spectrometry-based approaches:

  • Immunoprecipitate PRP38 using available antibodies (PRPF38A or PRPF38B)

  • Perform liquid chromatography-tandem mass spectrometry (LC-MS/MS)

  • Use fragmentation techniques optimized for PTM identification

• 2D gel electrophoresis:

  • Separate proteins based on isoelectric point and molecular weight

  • Identify PTM-dependent shifts in protein mobility

  • Confirm with Western blotting using PRP38 antibodies

• In vitro modification assays:

  • Incubate immunoprecipitated PRP38 with kinases, acetylases, or other modifying enzymes

  • Detect changes in modification status using mass spectrometry or Western blotting

  • Correlate modifications with functional changes

• Inhibitor studies:

  • Treat cells with inhibitors of specific PTM pathways

  • Observe effects on PRP38 function and spliceosome assembly

  • Monitor changes in pre-mRNA splicing patterns

• Site-directed mutagenesis:

  • Create mutants of potential modification sites

  • Compare effects of mutation with inhibition of the modification

  • Validate the importance of specific PTM sites

The difference between the calculated molecular weight (64 kDa) and observed molecular weight (65-70 kDa) of PRPF38B suggests the presence of post-translational modifications. Investigating these modifications could provide insights into regulatory mechanisms controlling spliceosome assembly and function.

How do PRP38 proteins differ across species, and what are the implications for antibody selection?

PRP38 proteins show evolutionary conservation across species, but with notable differences that affect antibody selection and experimental design:

• Evolutionary conservation and divergence:

  • PRP38 proteins are found from yeast to humans, indicating functional importance

  • The U4/U6.U5 tri-snRNP complex structure is conserved, but protein sequences may vary

  • Human has two homologs (PRPF38A and PRPF38B) while yeast has one (PRP38)

• Species-specific reactivity of antibodies:

  • PRPF38B antibody (23901-1-AP) reacts with human and mouse samples

  • PRPF38A antibody (PACO05548) also shows reactivity with human and mouse samples

  • Specific antibodies are available for yeast PRP38 (Saccharomyces cerevisiae and Schizosaccharomyces pombe)

• Cross-reactivity considerations:

  • Antibodies raised against human PRPF38 proteins may not recognize orthologs in distant species

  • Epitope conservation should be evaluated when using antibodies across species

  • Sequence alignment analysis can help predict potential cross-reactivity

• Model system selection:

  • For basic mechanistic studies, yeast models with specific anti-PRP38 antibodies may be advantageous

  • For disease-relevant research, mammalian models with PRPF38A or PRPF38B antibodies are appropriate

  • Consider evolutionary conservation of interaction partners and regulatory mechanisms

• Antibody selection strategy:

  • Select antibodies validated for your species of interest

  • Consider the immunogen sequence and its conservation across species

  • Test reactivity with recombinant proteins or lysates from different species when cross-species use is needed

Understanding the evolutionary relationships between PRP38 homologs can inform experimental design and interpretation, particularly when studying conserved mechanisms of spliceosome assembly and function across different model systems.